Clinical Trial Update: Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of an oral TEAD inhibitor from Ikena Oncology in adults with advanced solid tumors has been terminated. The trial included patients with malignant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelioid Hemangioendothelioma
• Malignant Pleural Mesothelioma

Drugs mentioned

• IK-930

Snippet

Sponsor: Ikena Oncology | Conditions: Solid Tumors, Adult, Solid Tumor | Phase 1 | Status: TERMINATED